Mingus
Well-known member
[SIZE=-1] Journal of Virology, July 2004, p. 7410-7417, Vol. 78, No. 14
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.14.7410-7417.2004
Copyright ? 2004, American Society for Microbiology. All Rights Reserved. [/SIZE]
Antiviral Drug Discovery Strategy Using Combinatorial Libraries of Structurally Constrained Peptides
El?onore Real,<sup>1</sup> Jean-Christophe Rain,<sup>2</sup> V?ronique Battaglia,<sup>2</sup> Corinne Jallet,<sup>1</sup> Pierre Perrin,<sup>1</sup> No?l Tordo,<sup>1</sup> Peggy Chrisment,<sup>3</sup> Jacques D'Alayer,<sup>3</sup> Pierre Legrain,<sup>2</sup> and Yves Jacob<sup>1</sup><sup>*</sup> D?partement de Virologie,<sup>1</sup> Laboratoire d'analyse et de micros?quen?age des prot?ines, Institut Pasteur, 75724 Paris Cedex 15,<sup>3</sup> Hybrigenics, 75014 Paris, France<sup>2</sup>
Received 11 December 2003/ Accepted 9 March 2004
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] ABSTRACT [/SIZE]</th></tr></tbody></table> <table align="right" border="1" cellpadding="5"><tbody><tr><th align="left">[SIZE=-1]
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
[/SIZE]</th></tr></tbody></table>
We have developed a new strategy for antiviral peptide discovery<sup> </sup>by using lyssaviruses (rabies virus and rabies-related viruses)<sup> </sup>as models. Based on the mimicry of natural bioactive peptides,<sup> </sup>two genetically encoded combinatorial peptide libraries composed<sup> </sup>of intrinsically constrained peptides (coactamers) were designed.<sup> </sup>Proteomic knowledge concerning the functional network of interactions<sup> </sup>in the lyssavirus transcription-replication complex highlights<sup> </sup>the phosphoprotein (P) as a prime target for inhibitors of viral<sup> </sup>replication. We present an integrated, sequential drug discovery<sup> </sup>process for selection of peptides with antiviral activity directed<sup> </sup>against the P. Our approach combines (i) an exhaustive two-hybrid<sup> </sup>selection of peptides binding two phylogenetically divergent<sup> </sup>lyssavirus P's, (ii) a functional analysis of protein interaction<sup> </sup>inhibition in a viral reverse genetic assay, coupled with a<sup> </sup>physical analysis of viral nucleoprotein-P complex by protein<sup> </sup>chip mass spectrometry, and (iii) an assay for inhibition of<sup> </sup>lyssavirus infection in mammalian cells. The validity of this<sup> </sup>strategy was demonstrated by the identification of four peptides<sup> </sup>exhibiting an efficient antiviral activity. Our work highlights<sup> </sup>the importance of P as a target in anti-rabies virus drug discovery.<sup> </sup>Furthermore, the screening strategy and the coactamer libraries<sup> </sup>presented in this report could be considered, respectively,<sup> </sup>a general target validation strategy and a potential source<sup> </sup>of biologically active peptides which could also help to design<sup> </sup>pharmacologically active peptide-mimicking molecules. The strategy<sup> </sup>described here is easily applicable to other pathogens.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] INTRODUCTION [/SIZE]</th></tr></tbody></table> <table align="right" border="1" cellpadding="5"><tbody><tr><th align="left">[SIZE=-1]
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
[/SIZE]</th></tr></tbody></table>
Our laboratory recently underscored the crucial role played<sup> </sup>by the phosphoprotein (P) in the formation of the rabies virus<sup> </sup>transcription-replication complex by using yeast two-hybrid<sup> </sup>and viral reverse genetic approaches (12). As a constituent<sup> </sup>of the viral ribonucleoprotein (RNP) complex, the P interacts<sup> </sup>with two other viral components, the nucleoprotein (N), which<sup> </sup>tightly enwraps the viral RNA genome, and the RNA-dependent<sup> </sup>RNA polymerase (L). P also binds a cellular protein implicated<sup> </sup>in retrograde transport (Dynein LC8), strongly suggesting that<sup> </sup>interfering with P functions could have deleterious effects<sup> </sup>on the viral cycle (11, 18). Thus, the pivotal roles played<sup> </sup>by P make it a prime target for inhibitors of viral transcription<sup> </sup>and replication.<sup> </sup>
A recent World Health Organization report estimated that between<sup> </sup>40,000 to 70,000 deaths from rabies encephalomyelitis occur<sup> </sup>every year (World Health Organization Fact Sheet No. 99, 2001),<sup> </sup>primarily due to the absence of an optimal postexposure treatment<sup> </sup>protocol for human vaccination and serotherapy (22). Rabies<sup> </sup>virus immunoglobulins of human or equine origin are in short<sup> </sup>supply worldwide and completely unaffordable in many developing<sup> </sup>countries. It is therefore urgent to find alternative solutions<sup> </sup>to treat the initial phase of rabies virus exposure. Local treatment<sup> </sup>with a virucidal drug would solve this problem, and development<sup> </sup>of anti-rabies virus peptides is of great interest in this respect.<sup> </sup>
The key aspects of antiviral drug development are, successively,<sup> </sup>as follows: the selection of a target and its validation, the<sup> </sup>development of screening assays, and finally, the preliminary<sup> </sup>identification of lead compounds. Numerous studies have demonstrated<sup> </sup>the interest of combinatorial approaches in the identification<sup> </sup>of short peptide sequences able to bind proteins (5, 6, 13,<sup> </sup>24). These studies have usually been performed with peptide<sup> </sup>aptamers (peptamers), a distinct class of molecules characterized<sup> </sup>by constrained peptidic loops displayed by a carrier protein<sup> </sup>(5). These molecules were used to counteract the conformational<sup> </sup>flexibility of linear peptides, which results otherwise in poor<sup> </sup>target binding. However, the fact that bioavailability of peptamers<sup> </sup>is determined by their scaffold-displaying protein is a critical<sup> </sup>limitation for the pharmacological potential of such peptides.<sup> </sup>In contrast, certain peptides found in nature are among the<sup> </sup>most pharmacologically active small molecules. Natural selection<sup> </sup>has favored a structurally sophisticated diversity, unified<sup> </sup>around a common characteristic: the presence of a constrained<sup> </sup>structure which decreases the conformational flexibility and<sup> </sup>thereby provides an improvement in specificity and stability.<sup> </sup>Among such autoconstrained peptides, toxins from predatory cone<sup> </sup>snail venoms (disulfide-constrained conotoxins) and insect antimicrobial<sup> </sup>proline-rich peptides (apidaecins and lebocins) can be considered<sup> </sup>the paradigms (1, 2, 10, 16, 17, 23).<sup> </sup>
The integrated antiviral drug discovery strategy developed here<sup> </sup>is based on the mimicry of these natural autoconstrained peptides.<sup> </sup>We have designed two coactamer libraries (from Latin coactus,<sup> </sup>constraint), that are rich in either cysteine or proline. The<sup> </sup>cysteine backbone mimics conotoxins-? from Conus geographus<sup> </sup>(16, 17, 23), and the proline backbone partially overlaps with<sup> </sup>lebocin 1 and 2 from Bombyx mori (1, 10).<sup> </sup>
Both genetically encoded combinatorial peptide libraries were<sup> </sup>screened by using a yeast two-hybrid system to identify peptides<sup> </sup>binding with high affinity to the P's from two highly divergent<sup> </sup>lyssaviruses (rabies Pasteur virus [PV] and Mokola virus [Mok])<sup> </sup>(15). To make the most exhaustive selection of P binders, the<sup> </sup>sequences of P-PV and P-Mok binding peptides were clustered<sup> </sup>into subfamilies by using a multiple-sequence alignment program.<sup> </sup>Based on these identified families, which cover a total of 755<sup> </sup>binders, 29 representative peptides were finally selected. These<sup> </sup>interacting peptides were then submitted to a functional screening<sup> </sup>step by designing a reverse genetic viral transcription-replication<sup> </sup>interference assay. In addition, the peptide effect on the viral<sup> </sup>RNP complex formation was analyzed by surface-enhanced laser<sup> </sup>desorption ionization-time of flight (mass spectrometry) [SELDI-TOF<sup> </sup>(MS)] analysis. Finally, peptides emerging as interactors and<sup> </sup>functional inhibitors of the transcription-replication complex<sup> </sup>were tested for their capacity to inhibit PV infection of mammalian<sup> </sup>cells. A flowchart representation summarizing the sequential<sup> </sup>peptide selection process is shown in Fig. 1.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
View larger version (30K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 1. Flow chart of the peptide selection process for antiviral activity juxtaposed with the corresponding numbers of selected peptides resulting from an exhaustive two-hybrid screening of 85.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> clones.
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] MATERIALS AND METHODS [/SIZE]</th></tr></tbody></table> <table align="right" border="1" cellpadding="5"><tbody><tr><th align="left">[SIZE=-1]
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
[/SIZE]</th></tr></tbody></table>
Combinatorial peptide libraries. Two long oligonucleotides encoding Cys and Pro constrained peptide<sup> </sup>libraries were synthesized. In both cases, 20 random codons<sup> </sup>are incorporated in a framework generated by constant cysteine<sup> </sup>or proline codons, flanked by sequences containing NcoI and<sup> </sup>BglII restriction sites for insertion in the vector pACTII (Clontech).<sup> </sup>Oligonucleotide C5, encoding cysteine-constrained peptides,<sup> </sup>was 5'-GCGCATGCCATGGAGGGGATCCGATGT(NNK)<sub>2</sub>TGT(NNK)<sub>5</sub>TGT(NNK)<sub>6</sub>TGT(NNK)<sub>5</sub>TGT(NNK)<sub>2</sub>TGTTAATAAGATCTCGCGTG-3'.<sup> </sup>Oligonucleotide C8, encoding proline-constrained peptides, was<sup> </sup>5'-GCGCATGCCATGGAGGGGATCCGACCACCT(NNK)<sub>5</sub>CCT(NNK)<sub>5</sub>CCTCCACCT(NNK)<sub>5</sub>CCT(NNK)<sub>5</sub>CCACCTTAATAAGATCTCGCGTG-3'.<sup> </sup> Oligonucleotides were synthesized on an Applied Biosystems 392<sup> </sup>synthesizer and contained triplets of the sequence NNK (where<sup> </sup>N is G, A, T, or C and K is G or C), which encodes all 20 amino<sup> </sup>acids but results in only one stop codon. To avoid synthesis<sup> </sup>bias, introduced by the chemical reactivity of each phosphoramidite,<sup> </sup>the N mix contained a final dN-CE phosphoramidite (Glen Research)<sup> </sup>concentration of 0.1 mmol/ml and a ratio of 3 dA/3 dC/2 dG/2<sup> </sup>dT. In contrast, the K mix contained equal proportions of dG<sup> </sup>and dC.<sup> </sup>
Second-strand synthesis was performed by PCR with the primers<sup> </sup>5'-GCGCATGCCATGGAGGGGATCC-3' and 5'-CACGCGAGATCTTATTAA-3'. The<sup> </sup>yeast strain Y187 (Clontech) was transformed with plasmid DNA<sup> </sup>by the lithium acetate procedure with plasmid DNA from 1 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup><sup> </sup>and 3 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup> primary Escherichia coli transformants, respectively,<sup> </sup>to give 2.1 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (cysteine coactamers) or 3.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (proline<sup> </sup>coactamers) individual yeast colonies, which were collected,<sup> </sup>pooled, and stored at ?80?C for each library (7).<sup> </sup>
Cloning procedures. Two-hybrid bait plasmids containing either the complete open<sup> </sup>reading frame of P-PV or P-Mok fused to the Gal4p-DNA binding<sup> </sup>domain were made by inserting the respective PCR-amplified fragments<sup> </sup>into the pAS2
vector (laboratoire du m?tabolisme des<sup> </sup>ARNs, Institut Pasteur) as described previously (7). Cloning<sup> </sup>junctions and the complete open reading frames were sequenced<sup> </sup>on an ABI 377 automatic sequencer (Applied Biosystems). High-throughput<sup> </sup>cloning of PCR products encoding selected peptides was performed<sup> </sup>by recombination cloning technology with the Gateway system<sup> </sup>(Invitrogen) as described previously (21). Plasmids pDEST53<sup> </sup>(Invitrogen) and pEGFP-C1 (Clontech) previously modified with<sup> </sup>the Gateway rf cassette were used as cloning vectors, respectively,<sup> </sup>for T7-driven peptide expression and mammalian expression of<sup> </sup>green fluorescent protein (GFP)-fused peptides. All plasmids<sup> </sup>were amplified in the E. coli strain DH5
and purified by chromatography<sup> </sup>on QIAGEN columns.<sup> </sup>
Yeast two-hybrid screening procedure. Two-hybrid screens were performed by using a cell-to-cell mating<sup> </sup>protocol (7). Saturated screens of libraries were performed<sup> </sup>to ensure total coverage of libraries. For each bait, a test<sup> </sup>screen was performed to optimize the screening conditions. The<sup> </sup>selectivity of the His3 reporter gene was modulated with 3-aminotriazole<sup> </sup>(Sigma) to obtain a maximum of 285 histidine-positive clones<sup> </sup>for 10 million diploids screened. For all selected clones, lacZ<sup> </sup>activity was measured in a 96-well plate luminometric assay<sup> </sup>(Tropix). Inserts of all positive clones were amplified by PCR<sup> </sup>(7) and then sequenced on an ABI 3700 automatic sequencer (Applied<sup> </sup>Biosystems).<sup> </sup>
Bioinformatic analyses. Screening results from the Cys and Pro libraries were analyzed<sup> </sup>separately. Amino acid sequences of selected P-PV and P-Mok<sup> </sup>binding peptides were compared and aligned. The clustering of<sup> </sup>these sequences into subfamilies was calculated and displayed<sup> </sup>with neighbor-joining and unweighted pair group methods with<sup> </sup>arithmetic mean dendrograms by using the Clustalw and Jalview<sup> </sup>programs (http://www.compbio.dundee.ac.uk/).<sup> </sup>
Viral transcription-replication interference assay. To measure the effect of peptide coexpression on the formation<sup> </sup>of the functional rabies virus transcription-replication complex,<sup> </sup>we used the viral reverse genetic assay as described previously<sup> </sup>(12). T7-driven pDEST53-peptide constructs were cotransfected<sup> </sup>(1 ?g) with the viral components (N, P, and L genes and<sup> </sup>luciferase negative-strand minigenomic RNA). Each of the 29<sup> </sup>pDEST53-peptide constructs was separately tested in duplicate.<sup> </sup>Interference in the functionality of the viral complex was quantified<sup> </sup>by measuring the amount of luciferase activity which is related<sup> </sup>to the remaining transcriptional activity of the RNP. Luciferase<sup> </sup>expression was measured with a Berthold luminometer by injecting<sup> </sup>100 ?l of luciferase assay reagent (E1501; Promega) into<sup> </sup>10 ?l of each centrifuged cellular extract and counting<sup> </sup>for 10 s.<sup> </sup>
SELDI-TOF ProteinChip MS analysis. Anti-Flag M2 monoclonal antibody (1.5 ?g M2 antibody;<sup> </sup>Sigma) was covalently cross-linked to preactivated ProteinChip<sup> </sup>arrays (PS20; Ciphergen) by incubation in a humidity chamber<sup> </sup>at room temperature for 1 h. Non-cross-linked sites were inactivated<sup> </sup>twice with 4 ?l of 1 M ethanolamine-HCl (pH 8.0) for 15<sup> </sup>min. The PS20 chip array was then assembled with a loading device<sup> </sup>(Bioprocessor) to wash each spot twice for 5 min with 300 ?l<sup> </sup>of 0.5% Triton X-100 in phosphate-buffered saline (PBS) followed<sup> </sup>by two washes with PBS (300 ?l).<sup> </sup>
After clarification by centrifugation at 3,900 [FONT=arial,helvetica]x[/FONT] g rpm (3 min),<sup> </sup>200-?l aliquots of a 48-h posttransfection cellular lysate,<sup> </sup>derived from a classical viral transcription-replication interference<sup> </sup>assay where P was replaced by flagged P, were spotted on the<sup> </sup>M2 antibody modified chip array and incubated at room temperature<sup> </sup>with gentle agitation for 2 h. The whole ProteinChip array was<sup> </sup>washed with PBS-0.1% Triton X-100 (300 ?l) and air dried<sup> </sup>after a brief wash with 5 mM HEPES (pH 7.5) (300 ?l).<sup> </sup>Then, to facilitate the ionization process, two successive volumes<sup> </sup>of 0.5 ?l of a saturated solution of sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic<sup> </sup>acid; Fluka) in 50% acetonitrile-0.5% trifluoroacetic acid were<sup> </sup>spotted on the array and allowed to air dry.<sup> </sup>
Analysis of the ProteinChip array was carried out in a PBS II<sup> </sup>mass reader (Ciphergen Biosystems, Inc). The data of each spot<sup> </sup>were averaged from 240 UV laser shots (intensity of 250) and<sup> </sup>analyzed by an automated data collection in positive mode and<sup> </sup>with an external calibration by using Ciphergen's standards<sup> </sup>(14).<sup> </sup>
Determination of inhibitory effect of peptides on cell infection by rabies virus. BSR cells were cultured in Labtek chambers (15,000 cells per<sup> </sup>chamber) for 24 h in Dulbecco's modified Eagle's medium (DMEM)<sup> </sup>supplemented with 10% fetal bovine serum at 37?C. Cells<sup> </sup>were transfected with 2 ?g of peptide-encoding plasmid<sup> </sup>with FuGENE (Roche Diagnostics) according to the manufacturer's<sup> </sup>protocol. At 6 h posttransfection, cell monolayers were washed<sup> </sup>twice with DMEM and then infected with rabies virus diluted<sup> </sup>in DMEM (PV strain, 5 PFU/cell). After incubation for 1 h, the<sup> </sup>medium was discarded, and cells were washed with DMEM and then<sup> </sup>incubated at 37?C and 5% CO<sub>2</sub> for 24 h in DMEM supplemented<sup> </sup>with 5% fetal bovine serum.<sup> </sup>
Infected cells were fixed with PBS-4% paraformaldehyde and permeabilized<sup> </sup>at 0?C with 80% acetone for 15 min. Rabies virus RNP generated<sup> </sup>by the infection were then detected by incubation of fixed cells<sup> </sup>with rabbit anti-RNP serum (incubation for 1 h at 37?C)<sup> </sup>followed by incubation with Texas Red anti-rabbit conjugate<sup> </sup>under the same experimental conditions. The detection of infected<sup> </sup>and transfected cells with the control GFP fusion expression<sup> </sup>vector was determined by immunofluorescence analysis (LEICA<sup> </sup>DMRB microscope). Under these conditions, 75 to 80% of cells<sup> </sup>were found infected, whereas 30 to 50% of cells were GFP positive,<sup> </sup>depending on the plasmid used.<sup> </sup>
The inhibition percentage of transfected cells expressing the<sup> </sup>peptide-GFP fusion was calculated as follows: [1 ? (percentage<sup> </sup>of peptide-GFP rabies virus-infected cells/percentage of control-GFP<sup> </sup>rabies virus-infected cells)] [FONT=arial,helvetica]x[/FONT] 100. For each duplicate, 50<sup> </sup>GFP-positive cells were examined for the presence of rabies<sup> </sup>virus RNP.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] RESULTS [/SIZE]</th></tr></tbody></table> <table align="right" border="1" cellpadding="5"><tbody><tr><th align="left">[SIZE=-1]
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
[/SIZE]</th></tr></tbody></table>
Design of coactamer libraries. Two libraries were constructed to direct the synthesis in yeast<sup> </sup>of various intrinsically constrained peptides fused to the Gal4p<sup> </sup>activation domain. The peptide-encoding libraries based on the<sup> </sup>mimicry of natural bioactive peptides share the presence of<sup> </sup>an invariable backbone of either cysteine or proline residues<sup> </sup>delimiting hypervariable peptide loops. In each of our libraries,<sup> </sup>20 amino acid residues are hypervariable within a peptide total<sup> </sup>length of either 26 or 29 amino acid residues for the cysteine<sup> </sup>and proline libraries, respectively. The cysteine coactamer<sup> </sup>library sequence was C-X<sub>2</sub>-C-X<sub>5</sub>-C-X<sub>6</sub>-C-X<sub>5</sub>-C-X<sub>2</sub>-C, and the proline<sup> </sup>coactamer library sequence was PP-X<sub>5</sub>-P-X<sub>5</sub>-PPP-X<sub>5</sub>-P-X<sub>5</sub>-PP. In<sup> </sup>both sequences, X denotes a randomized position where an NNK<sup> </sup>degenerate DNA codon encodes all 20 natural amino acids. Moreover,<sup> </sup>the cysteine-rich backbone was designed to fit to a typical<sup> </sup>Cys<sub>2</sub>/Cys<sub>2</sub> zinc finger motif which would favor organometallic<sup> </sup>complex formation and potentially increase the structural diversity<sup> </sup>of the cysteine coactamer library. The cysteine and proline<sup> </sup>libraries have an estimated diversity of 1 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup> and 3 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup><sup> </sup>individual random peptides. Sequencing of 20 randomly chosen<sup> </sup>clones in each library showed 100% insertion rates. Respectively,<sup> </sup>37 and 47% of the clones in the cysteine and proline libraries<sup> </sup>coded for full-length peptides. Other clones corresponded to<sup> </sup>shortened versions, resulting from the occurrence of frameshifts<sup> </sup>and termination codons. Yeast strain Y187 was transformed with<sup> </sup>each library, generating two yeast coactamer libraries with<sup> </sup>estimated individual complexities of 2.1 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (cysteine coactamers)<sup> </sup>and 3.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (proline coactamers).<sup> </sup>
Identification of P-binding peptides. We screened the two coactamer libraries with two highly divergent<sup> </sup>but functionally interchangeable P's (12) derived from two phylogenetically<sup> </sup>distant lyssaviruses (PV and Mok) (15). Thus, selectivity of<sup> </sup>the screening procedure could be reinforced by cross-selection<sup> </sup>for interactors common to both baits. The results of these screening<sup> </sup>assays are presented in Table 1. The saturation of the screens<sup> </sup>was confirmed by the redundancy in the peptide sequences (see<sup> </sup>peptide occurrence in Table 2). The number of positive clones<sup> </sup>per million interactions tested shows that the P-Mok bait has<sup> </sup>selected six times more prey than the P-PV bait with both libraries<sup> </sup>(Table 1). The screening of both libraries with a Trp+ empty<sup> </sup>vector (pFL 39) (8) allowed us to discard seven false-positive<sup> </sup>prey selected in the cysteine constraint library with P-PV and<sup> </sup>P-Mok (data not shown). No such overlap was observed for the<sup> </sup>proline coactamer library screening.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 1. Yeast two-hybrid screening results
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 2. Characteristics of selected peptides
</td></tr></tbody></table> </td></tr></tbody></table></center>
Bioinformatic selection of peptides. In silico analysis with multialignment programs (ClustalW with<sup> </sup>Jalview display) was used to compare the sequence data of interacting<sup> </sup>peptides selected by both P-PV and P-Mok baits from each coactamer<sup> </sup>library screen. A total of 755 selected clones were analyzed<sup> </sup>(Table 1). The preliminary output obtained by computer program<sup> </sup>analysis revealed subfamilies of peptides characterized by sequence<sup> </sup>similarity. Based on this multiple-sequence comparison, to maximize<sup> </sup>the sequence diversity of the peptides retained for further<sup> </sup>experiments, one member of each identified subfamily of similarity<sup> </sup>was selected. This selection also took into account the most<sup> </sup>frequently occurring peptides and thus the total representativity<sup> </sup>of each subfamily. Thus, 11 Cys and 17 Pro peptides were selected.<sup> </sup>In addition, one Cys peptide monospecific for P-PV was also<sup> </sup>chosen for further analysis.<sup> </sup> Functional test of viral transcription-replication complex formation interference assay. Each of the 29 selected peptides was subcloned in a T7 mammalian<sup> </sup>expression vector and then tested in a reverse genetic viral<sup> </sup>RNP reconstitution assay. This assay allows a quantitative analysis<sup> </sup>of the formation of a functional viral RNP by luciferase activity<sup> </sup>measurement (12). By coexpressing each individual peptide in<sup> </sup>this assay, we measured its capacity to interfere with the viral<sup> </sup>transcription-replication complex (Fig. 2). The 100% value corresponds<sup> </sup>to the control experiment realized with the peptide expression<sup> </sup>vector without the peptide-encoding sequence (empty vector),<sup> </sup>giving an average luciferase activity of about 10<sup>6</sup> arbitrary<sup> </sup>units. The background was below 100 arbitrary units.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
View larger version (13K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 2. Interference effects of selected peptides on the transcription-replication activity of rabies virus PV RNP complex (shown as means ? standard errors [error bars]). The luciferase activity was indicated as 100% in the control experiment with the empty peptide expression vector (y axis). One hundred percent corresponds to an average luciferase activity of 10<sup>6</sup> units. The experiment was performed in duplicate.
</td></tr></tbody></table> </td></tr></tbody></table></center>
In this assay, the majority of the selected peptides was fully<sup> </sup>active, except for P11, P19, and C26. The latter was chosen<sup> </sup>as an internal control because of its monospecificity and single<sup> </sup>occurrence. This underlines the utility of a screening strategy<sup> </sup>with two different baits in yeast two-hybrid analysis. This<sup> </sup>approach provided functional data that could be superposed on<sup> </sup>the initial selection procedure and allowed us to select the<sup> </sup>10 most active peptides plus a weak one as a control (C26).<sup> </sup>The selected peptides were submitted to a biophysical analysis<sup> </sup>of RNP complex destabilization.<sup> </sup> SELDI-TOF ProteinChip MS analysis. To evaluate whether functional inhibition of the RNP complex<sup> </sup>could be correlated with an alteration of the N-P interaction,<sup> </sup>we developed a method by using a Ciphergen Biosystems mass spectrometer<sup> </sup>which associates ProteinChip technology with SELDI-TOF (MS).<sup> </sup>Briefly, this assay consists of a classical coimmunoprecipitation<sup> </sup>experiment in which the anti-Flag M2 monoclonal antibody is<sup> </sup>covalently cross-linked with an epoxy preactivated ProteinChip<sup> </sup>array (PS20) instead of using protein A-Sepharose beads as the<sup> </sup>immunoabsorbant. Protein extracts are prepared from cells cotransfected<sup> </sup>with plasmids coding for N and L, the rabies virus minigenome,<sup> </sup>and a flagged P-PV, which works as a hook allowing RNP complex<sup> </sup>retention and subsequent analysis by classical SELDI-TOF (MS).<sup> </sup>Using this approach, alterations in the protein profiling of<sup> </sup>the rabies virus N-P complex in the presence of coexpressed<sup> </sup>peptide can then be measured. By comparison with a control experiment<sup> </sup>without peptide (B spectrum) (Fig. 3), the destabilization of<sup> </sup>the N-P interaction is correlated to an increase in the P/N<sup> </sup>peak intensity ratio (Table 3). Characteristic spectra observed<sup> </sup>with different peptides are shown in Fig. 3. The C2 and P16<sup> </sup>peptides clearly destabilize the N-P interaction, whereas the<sup> </sup>C9 or C26 peptide had little or no effect on the N-P complex.<sup> </sup>As the N-P interaction plays a crucial role in the functionality<sup> </sup>of the viral replication-transcription complex, N-P interaction<sup> </sup>destabilization was used as a criterion to select six interfering<sup> </sup>peptides characterized by their increasing effects, two other<sup> </sup>peptides were kept as negative controls (C26 and C27) (Table<sup> </sup>3). As peptides P15 and P16 displayed similar SELDI-TOF (MS)<sup> </sup>profiles, only P16 was kept. Quantification of P and peptide<sup> </sup>expression levels in the mammalian cells used in the interference<sup> </sup>assay or SELDI-TOF experiments show a peptide/P ratio of 1,<sup> </sup>with a 30 nM concentration of each in the various cell extracts<sup> </sup>(data not shown).<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
View larger version (26K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 3. Representative protein profiling of rabies virus N/P complex by ProteinChip SELDI-TOF (MS) analysis. Panels A and B correspond to control (Ctl) experiments with untransfected and RNP-expressing cells, respectively, and panels C, D, E, and F show results from peptide experiments.
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 3. Evaluation of N-P interaction destabilization by ProteinChip SELDI-TOF(MS)
</td></tr></tbody></table> </td></tr></tbody></table></center>
Inhibition of viral replication assay. To evaluate the antiviral activity of the 8 last selected peptides,<sup> </sup>they were subcloned into a GFP fusion mammalian expression vector<sup> </sup>(enhanced GFP-C1; Clontech). The rabies virus inhibition of<sup> </sup>replication assay consists of the transfection of BSR cells<sup> </sup>with plasmids encoding the peptides followed by infection with<sup> </sup>rabies virus (Table 4). One peptide (P29) was discarded because<sup> </sup>of its cytotoxic activity. Four peptides (C2, C6, C8, and P16)<sup> </sup>demonstrated a strong antiviral activity. Peptide C10, although<sup> </sup>slightly less active (57% inhibition), strongly reduced the<sup> </sup>size and number of virus inclusion bodies. However, this modification<sup> </sup>of the appearance of infected cells was not taken into consideration<sup> </sup>for the evaluation of inhibition, resulting in a potential underestimation<sup> </sup>of total antiviral activity.<sup> </sup> <!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 4. Inhibition of rabies virus replication in PV rabies-infected BSR cells
</td></tr></tbody></table> </td></tr></tbody></table></center>
The inhibitory activity of two peptides (C2 and P16) is illustrated<sup> </sup>in Fig. 4. Whereas 75 to 80% of cells were infected under the<sup> </sup>infection conditions used (as measured by RNP production; data<sup> </sup>not shown), the majority of transfected cells expressing selected<sup> </sup>peptides (as indicated by GFP expression) were found to be negative<sup> </sup>for rabies virus RNP expression (Fig. 4A to F), indicating high<sup> </sup>levels of virus inhibitory activity. In contrast, cells transfected<sup> </sup>with the control plasmid expressing GFP (control experiment)<sup> </sup>displayed a normal expression level of rabies virus RNP (Fig.<sup> </sup>4G to I) and no inhibition.<sup> </sup> <!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
View larger version (47K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 4. Inhibitory effect of peptides on infection by rabies virus. BSR cells were transfected with C2 plasmid (A to C), P16 plasmid (D to F), or empty plasmid in a control experiment (G to I). (A, D, and G) GFP fluorescence (note granular inclusions of GFP fusion with peptide C2 or P16); (B, E, and H) rabies virus RNP immunostaining with characteristic perinuclear dots (white arrows indicate transfected cells); (C, F, and I) merged GFP and rabies virus RNP immunostaining with 4',6'-diamidino-2-phenylindole (DAPI) coloration of cell nuclei. The majority of transfected cells expressing selected peptides (indicated by GFP expression) were found to be negative for rabies virus RNP.
</td></tr></tbody></table> </td></tr></tbody></table></center>
In summary, our results clearly indicate that selected peptides<sup> </sup>destabilize both the interaction and functionality of the lyssavirus<sup> </sup>N-P complex, an interference which could be detected in a viral<sup> </sup>reverse genetic assay, a particle-complex physical analysis,<sup> </sup>and a cell infection test.<sup> </sup> <!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] DISCUSSION [/SIZE]</th></tr></tbody></table> <table align="right" border="1" cellpadding="5"><tbody><tr><th align="left">[SIZE=-1]
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
[/SIZE]</th></tr></tbody></table>
The rabies virus P is a main component of the RNP, providing<sup> </sup>the link between the N-enwrapped genomic RNA and the viral polymerase<sup> </sup>(3, 4, 12) and playing a role in retrograde transport through<sup> </sup>its interaction with cytoplasmic dynein (11, 18). All of these<sup> </sup>data suggest that rabies virus P could be a prime antiviral<sup> </sup>target. Moreover, rabies virus P was successfully used as a<sup> </sup>bait in previous two-hybrid screens (11, 12, 18), indicating<sup> </sup>that the resulting GAL4 binding domain-P fusion folds correctly<sup> </sup>in yeast cells.<sup> </sup>
Many studies with peptide aptamers have demonstrated the interest<sup> </sup>of combinatorial approaches in the identification of short peptide<sup> </sup>sequences able to mimic the large array of structures that characterize<sup> </sup>cellular proteomes. To be biologically active, these peptide<sup> </sup>aptamers (peptamers) require conformational constraints that<sup> </sup>are induced by their carrier proteins. In contrast to such peptamers,<sup> </sup>the coactamer concept developed in this study uses intrinsically<sup> </sup>constrained peptides mimicking natural bioactive peptides. Our<sup> </sup>approach involves a sequence of selective steps of increasing<sup> </sup>stringency, going from identification of interactors to functional<sup> </sup>inhibitors. Of the 755 P-binding peptides first selected in<sup> </sup>an exhaustive two-hybrid screening, in silico analysis identified<sup> </sup>subfamilies from which the most representative peptides were<sup> </sup>chosen by using as selection requirements both their frequency<sup> </sup>and their ability to bind to two lyssavirus P's (PV and Mok).<sup> </sup>These two highly divergent P's were previously demonstrated<sup> </sup>to be functionally interchangeable in a reverse genetic assay<sup> </sup>(12) and thus were chosen to reinforce the stringency of the<sup> </sup>selection process. This assumes that the interacting peptides<sup> </sup>common to both baits were binders to conserved functional regions,<sup> </sup>given that the 47% identity between the two P's is restricted<sup> </sup>to functionally important domains (12). Thus, peptides binding<sup> </sup>to both proteins are likely to interfere more strongly with<sup> </sup>the viral infectious cycle. This double selection in the two-hybrid<sup> </sup>procedure was combined with a viral reverse genetic assay consisting<sup> </sup>of an ex vivo reconstitution of a functional transcription-replication<sup> </sup>complex. A rather high proportion of peptides selected in this<sup> </sup>study are biologically active. As previously demonstrated with<sup> </sup>single-stranded antibody selection, this is likely to be related<sup> </sup>to the use of an in vivo selection (here, the yeast two-hybrid<sup> </sup>and the viral reverse genetic assay), which should facilitate<sup> </sup>the identification of in vivo valuable peptides (20). Peptides<sup> </sup>emerging as both P-interactors and the strongest transcription-replication<sup> </sup>inhibitors were studied with ProteinChip MS analysis for their<sup> </sup>capacity to destabilize the N-P interaction. Only partial destabilization<sup> </sup>was achieved with inhibitory peptides, which is in good agreement<sup> </sup>with the peptide/target ratio close to 1 which was observed<sup> </sup>under our experimental conditions. For the peptides C9 and P23,<sup> </sup>which were inhibitory in the viral reverse genetic assay but<sup> </sup>displayed no measurable destabilization of the N-P interaction,<sup> </sup>it seems likely that they may interfere with interactions, such<sup> </sup>as that of P and L, that also play a pivotal role in rabies<sup> </sup>virus RNP complex function. Unfortunately, the size discrepancy<sup> </sup>between L (220 kDa) and P (35 kDa) invalidates further investigations<sup> </sup>with ProteinChip MS analysis. Considering the lack of mechanistic<sup> </sup>evidence for some peptides, we have favored for further analysis<sup> </sup>only six peptides essentially characterized by their different<sup> </sup>SELDI-TOF (MS) profiles with increasing effects on N-P destabilization.<sup> </sup>This highly stringent selection might possibly have resulted<sup> </sup>in missing some of the peptides that would also be effective<sup> </sup>in suppressing the viral replication. Alternatively, a more<sup> </sup>pragmatic approach could also be envisaged, consisting of the<sup> </sup>direct selection of peptides for their antiviral activities<sup> </sup>and then of the investigation of the suppressive mechanism,<sup> </sup>provided that a multiparallel inhibition of infection assay<sup> </sup>could be designed. In this work, as the ultimate validation<sup> </sup>of our overall strategy for the identification of antiviral<sup> </sup>peptides, we have performed an ex vivo inhibition of viral replication<sup> </sup>assay with rabies virus. This assay constituted the most stringent<sup> </sup>test and resulted in the identification of four strong rabies<sup> </sup>virus inhibitory peptides (C2, C6, C8, and P16) whose general<sup> </sup>features in comparison with control peptides are displayed in<sup> </sup>Table 5. The overall structural diversity of the four strongest<sup> </sup>bioactive peptides suggests that a mixture of them could potentiate<sup> </sup>their therapeutic effect by affecting different P functional<sup> </sup>domains. Furthermore, these four peptides demonstrated no inhibition<sup> </sup>of cellular infection with the unrelated human immunodeficiency<sup> </sup>virus (HIV) type 1, further underscoring the specificity of<sup> </sup>the selected peptides for the rabies virus targets (data not<sup> </sup>shown).<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 5. General features of selected bioactive and control peptides
</td></tr></tbody></table> </td></tr></tbody></table></center>
Interestingly, despite a larger selection of prey in the proline<sup> </sup>library, cysteine coactamers seem to be more active, suggesting<sup> </sup>that the presence of cysteine favors constraints inducing greater<sup> </sup>stability and affinity of interacting peptides. Structure prediction<sup> </sup>with the PROF algorithm within the PredictProtein program indicated<sup> </sup>that three peptides (C6, C8, and P16) have an overall propensity<sup> </sup>to assume an alpha-helical conformation. In contrast, peptide<sup> </sup>C2, which is the most active, did not exhibit significant helical<sup> </sup>content, suggesting that maximizing the helical content of a<sup> </sup>short peptide could constrain it into a rigid helix with no<sup> </sup>significant increase in inhibitory potency and binding affinity.<sup> </sup> Finally, the peptides identified in this report may be considered<sup> </sup>molecular starting points that are likely to facilitate the<sup> </sup>design of nonpeptide mimics chemically engineered via scaffolding<sup> </sup>approaches. It should be noted that proline-rich peptides could<sup> </sup>facilitate the development of peptidomimetic approaches, which<sup> </sup>frequently use alpha-substituted proline analogues. Alternatively,<sup> </sup>these peptides, after a tailored mutagenesis to generate super<sup> </sup>binders and the addition of a protein transduction domain such<sup> </sup>as HIV TAT (19) or Antennapedia peptide, could be directly submitted<sup> </sup>to pharmacological tests. Indeed, the use of peptide-mediated<sup> </sup>transduction, through arginine-rich segments (9), is currently<sup> </sup>being investigated for therapeutic use in animals.<sup> </sup>
Interestingly, in preliminary experiments for establishing the<sup> </sup>cysteine-rich peptide library in yeast cells, we selected peptides<sup> </sup>able to bind DNA on the His<sub>3</sub> promoter region (data not shown).<sup> </sup>Thus, the cysteine coactamer library may also be useful for<sup> </sup>the identification of a specific DNA binding peptide which could<sup> </sup>be screened in yeast one-hybrid experiments. For DNA viruses,<sup> </sup>the identification of specific binders of viral regulatory regions<sup> </sup>represents an interesting potential antiviral strategy which<sup> </sup>could complement the targeting of viral proteins.<sup> </sup>
In summary, this work shows that coactamer libraries are powerful<sup> </sup>tools for target validation as exemplified here in anti-rabies<sup> </sup>virus drug discovery with the viral P as a target. The resulting<sup> </sup>libraries are also valuable sources of novel molecules with<sup> </sup>implications for the development of a new type of anti-rabies<sup> </sup>virus treatment. Moreover, this conceptual approach and its<sup> </sup>related tools are applicable to other infectious diseases and<sup> </sup>in any context of pathway-based drug discovery.<sup> </sup>
<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] ACKNOWLEDGMENTS [/SIZE]</th></tr></tbody></table>
We thank Dinh Tam Huynh, Val?rie Huteau, and Catherine<sup> </sup>Gouyette for the special care given to synthesizing the long<sup> </sup>random oligonucleotides and Charles Roth and Andrew Borman for<sup> </sup>helpful discussions. We are indebted to Luc Selig for his important<sup> </sup>contribution to this work, and we thank Stephane Emiliani from<sup> </sup>INSERM U567 (Institut Cochin) for performing HIV type 1 cellular<sup> </sup>infection tests.<sup> </sup>
E.R. was a recipient of an M.E.N.R.T. fellowship.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
</td> <th align="left" valign="middle" width="95%">[SIZE=+2] FOOTNOTES [/SIZE]</th></tr></tbody></table>
<!-- null --> * Corresponding author. Mailing address: Pasteur Institute, Departement de Virologie, 28, rue du Dr Roux, Paris 75015, France. Phone: 33 1 45 68 87 53. Fax: 33 1 45 68 89 66. E-mail: yjacob@pasteur.fr<script type="text/javascript"><!-- var u = "yjacob", d = "pasteur.fr"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script>.
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.14.7410-7417.2004
Copyright ? 2004, American Society for Microbiology. All Rights Reserved. [/SIZE]
Antiviral Drug Discovery Strategy Using Combinatorial Libraries of Structurally Constrained Peptides
El?onore Real,<sup>1</sup> Jean-Christophe Rain,<sup>2</sup> V?ronique Battaglia,<sup>2</sup> Corinne Jallet,<sup>1</sup> Pierre Perrin,<sup>1</sup> No?l Tordo,<sup>1</sup> Peggy Chrisment,<sup>3</sup> Jacques D'Alayer,<sup>3</sup> Pierre Legrain,<sup>2</sup> and Yves Jacob<sup>1</sup><sup>*</sup> D?partement de Virologie,<sup>1</sup> Laboratoire d'analyse et de micros?quen?age des prot?ines, Institut Pasteur, 75724 Paris Cedex 15,<sup>3</sup> Hybrigenics, 75014 Paris, France<sup>2</sup>
Received 11 December 2003/ Accepted 9 March 2004
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
[/SIZE]</th></tr></tbody></table>
We have developed a new strategy for antiviral peptide discovery<sup> </sup>by using lyssaviruses (rabies virus and rabies-related viruses)<sup> </sup>as models. Based on the mimicry of natural bioactive peptides,<sup> </sup>two genetically encoded combinatorial peptide libraries composed<sup> </sup>of intrinsically constrained peptides (coactamers) were designed.<sup> </sup>Proteomic knowledge concerning the functional network of interactions<sup> </sup>in the lyssavirus transcription-replication complex highlights<sup> </sup>the phosphoprotein (P) as a prime target for inhibitors of viral<sup> </sup>replication. We present an integrated, sequential drug discovery<sup> </sup>process for selection of peptides with antiviral activity directed<sup> </sup>against the P. Our approach combines (i) an exhaustive two-hybrid<sup> </sup>selection of peptides binding two phylogenetically divergent<sup> </sup>lyssavirus P's, (ii) a functional analysis of protein interaction<sup> </sup>inhibition in a viral reverse genetic assay, coupled with a<sup> </sup>physical analysis of viral nucleoprotein-P complex by protein<sup> </sup>chip mass spectrometry, and (iii) an assay for inhibition of<sup> </sup>lyssavirus infection in mammalian cells. The validity of this<sup> </sup>strategy was demonstrated by the identification of four peptides<sup> </sup>exhibiting an efficient antiviral activity. Our work highlights<sup> </sup>the importance of P as a target in anti-rabies virus drug discovery.<sup> </sup>Furthermore, the screening strategy and the coactamer libraries<sup> </sup>presented in this report could be considered, respectively,<sup> </sup>a general target validation strategy and a potential source<sup> </sup>of biologically active peptides which could also help to design<sup> </sup>pharmacologically active peptide-mimicking molecules. The strategy<sup> </sup>described here is easily applicable to other pathogens.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
[/SIZE]</th></tr></tbody></table>
Our laboratory recently underscored the crucial role played<sup> </sup>by the phosphoprotein (P) in the formation of the rabies virus<sup> </sup>transcription-replication complex by using yeast two-hybrid<sup> </sup>and viral reverse genetic approaches (12). As a constituent<sup> </sup>of the viral ribonucleoprotein (RNP) complex, the P interacts<sup> </sup>with two other viral components, the nucleoprotein (N), which<sup> </sup>tightly enwraps the viral RNA genome, and the RNA-dependent<sup> </sup>RNA polymerase (L). P also binds a cellular protein implicated<sup> </sup>in retrograde transport (Dynein LC8), strongly suggesting that<sup> </sup>interfering with P functions could have deleterious effects<sup> </sup>on the viral cycle (11, 18). Thus, the pivotal roles played<sup> </sup>by P make it a prime target for inhibitors of viral transcription<sup> </sup>and replication.<sup> </sup>
A recent World Health Organization report estimated that between<sup> </sup>40,000 to 70,000 deaths from rabies encephalomyelitis occur<sup> </sup>every year (World Health Organization Fact Sheet No. 99, 2001),<sup> </sup>primarily due to the absence of an optimal postexposure treatment<sup> </sup>protocol for human vaccination and serotherapy (22). Rabies<sup> </sup>virus immunoglobulins of human or equine origin are in short<sup> </sup>supply worldwide and completely unaffordable in many developing<sup> </sup>countries. It is therefore urgent to find alternative solutions<sup> </sup>to treat the initial phase of rabies virus exposure. Local treatment<sup> </sup>with a virucidal drug would solve this problem, and development<sup> </sup>of anti-rabies virus peptides is of great interest in this respect.<sup> </sup>
The key aspects of antiviral drug development are, successively,<sup> </sup>as follows: the selection of a target and its validation, the<sup> </sup>development of screening assays, and finally, the preliminary<sup> </sup>identification of lead compounds. Numerous studies have demonstrated<sup> </sup>the interest of combinatorial approaches in the identification<sup> </sup>of short peptide sequences able to bind proteins (5, 6, 13,<sup> </sup>24). These studies have usually been performed with peptide<sup> </sup>aptamers (peptamers), a distinct class of molecules characterized<sup> </sup>by constrained peptidic loops displayed by a carrier protein<sup> </sup>(5). These molecules were used to counteract the conformational<sup> </sup>flexibility of linear peptides, which results otherwise in poor<sup> </sup>target binding. However, the fact that bioavailability of peptamers<sup> </sup>is determined by their scaffold-displaying protein is a critical<sup> </sup>limitation for the pharmacological potential of such peptides.<sup> </sup>In contrast, certain peptides found in nature are among the<sup> </sup>most pharmacologically active small molecules. Natural selection<sup> </sup>has favored a structurally sophisticated diversity, unified<sup> </sup>around a common characteristic: the presence of a constrained<sup> </sup>structure which decreases the conformational flexibility and<sup> </sup>thereby provides an improvement in specificity and stability.<sup> </sup>Among such autoconstrained peptides, toxins from predatory cone<sup> </sup>snail venoms (disulfide-constrained conotoxins) and insect antimicrobial<sup> </sup>proline-rich peptides (apidaecins and lebocins) can be considered<sup> </sup>the paradigms (1, 2, 10, 16, 17, 23).<sup> </sup>
The integrated antiviral drug discovery strategy developed here<sup> </sup>is based on the mimicry of these natural autoconstrained peptides.<sup> </sup>We have designed two coactamer libraries (from Latin coactus,<sup> </sup>constraint), that are rich in either cysteine or proline. The<sup> </sup>cysteine backbone mimics conotoxins-? from Conus geographus<sup> </sup>(16, 17, 23), and the proline backbone partially overlaps with<sup> </sup>lebocin 1 and 2 from Bombyx mori (1, 10).<sup> </sup>
Both genetically encoded combinatorial peptide libraries were<sup> </sup>screened by using a yeast two-hybrid system to identify peptides<sup> </sup>binding with high affinity to the P's from two highly divergent<sup> </sup>lyssaviruses (rabies Pasteur virus [PV] and Mokola virus [Mok])<sup> </sup>(15). To make the most exhaustive selection of P binders, the<sup> </sup>sequences of P-PV and P-Mok binding peptides were clustered<sup> </sup>into subfamilies by using a multiple-sequence alignment program.<sup> </sup>Based on these identified families, which cover a total of 755<sup> </sup>binders, 29 representative peptides were finally selected. These<sup> </sup>interacting peptides were then submitted to a functional screening<sup> </sup>step by designing a reverse genetic viral transcription-replication<sup> </sup>interference assay. In addition, the peptide effect on the viral<sup> </sup>RNP complex formation was analyzed by surface-enhanced laser<sup> </sup>desorption ionization-time of flight (mass spectrometry) [SELDI-TOF<sup> </sup>(MS)] analysis. Finally, peptides emerging as interactors and<sup> </sup>functional inhibitors of the transcription-replication complex<sup> </sup>were tested for their capacity to inhibit PV infection of mammalian<sup> </sup>cells. A flowchart representation summarizing the sequential<sup> </sup>peptide selection process is shown in Fig. 1.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">

View larger version (30K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 1. Flow chart of the peptide selection process for antiviral activity juxtaposed with the corresponding numbers of selected peptides resulting from an exhaustive two-hybrid screening of 85.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> clones.
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
[/SIZE]</th></tr></tbody></table>
Combinatorial peptide libraries. Two long oligonucleotides encoding Cys and Pro constrained peptide<sup> </sup>libraries were synthesized. In both cases, 20 random codons<sup> </sup>are incorporated in a framework generated by constant cysteine<sup> </sup>or proline codons, flanked by sequences containing NcoI and<sup> </sup>BglII restriction sites for insertion in the vector pACTII (Clontech).<sup> </sup>Oligonucleotide C5, encoding cysteine-constrained peptides,<sup> </sup>was 5'-GCGCATGCCATGGAGGGGATCCGATGT(NNK)<sub>2</sub>TGT(NNK)<sub>5</sub>TGT(NNK)<sub>6</sub>TGT(NNK)<sub>5</sub>TGT(NNK)<sub>2</sub>TGTTAATAAGATCTCGCGTG-3'.<sup> </sup>Oligonucleotide C8, encoding proline-constrained peptides, was<sup> </sup>5'-GCGCATGCCATGGAGGGGATCCGACCACCT(NNK)<sub>5</sub>CCT(NNK)<sub>5</sub>CCTCCACCT(NNK)<sub>5</sub>CCT(NNK)<sub>5</sub>CCACCTTAATAAGATCTCGCGTG-3'.<sup> </sup> Oligonucleotides were synthesized on an Applied Biosystems 392<sup> </sup>synthesizer and contained triplets of the sequence NNK (where<sup> </sup>N is G, A, T, or C and K is G or C), which encodes all 20 amino<sup> </sup>acids but results in only one stop codon. To avoid synthesis<sup> </sup>bias, introduced by the chemical reactivity of each phosphoramidite,<sup> </sup>the N mix contained a final dN-CE phosphoramidite (Glen Research)<sup> </sup>concentration of 0.1 mmol/ml and a ratio of 3 dA/3 dC/2 dG/2<sup> </sup>dT. In contrast, the K mix contained equal proportions of dG<sup> </sup>and dC.<sup> </sup>
Second-strand synthesis was performed by PCR with the primers<sup> </sup>5'-GCGCATGCCATGGAGGGGATCC-3' and 5'-CACGCGAGATCTTATTAA-3'. The<sup> </sup>yeast strain Y187 (Clontech) was transformed with plasmid DNA<sup> </sup>by the lithium acetate procedure with plasmid DNA from 1 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup><sup> </sup>and 3 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup> primary Escherichia coli transformants, respectively,<sup> </sup>to give 2.1 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (cysteine coactamers) or 3.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (proline<sup> </sup>coactamers) individual yeast colonies, which were collected,<sup> </sup>pooled, and stored at ?80?C for each library (7).<sup> </sup>
Cloning procedures. Two-hybrid bait plasmids containing either the complete open<sup> </sup>reading frame of P-PV or P-Mok fused to the Gal4p-DNA binding<sup> </sup>domain were made by inserting the respective PCR-amplified fragments<sup> </sup>into the pAS2
Yeast two-hybrid screening procedure. Two-hybrid screens were performed by using a cell-to-cell mating<sup> </sup>protocol (7). Saturated screens of libraries were performed<sup> </sup>to ensure total coverage of libraries. For each bait, a test<sup> </sup>screen was performed to optimize the screening conditions. The<sup> </sup>selectivity of the His3 reporter gene was modulated with 3-aminotriazole<sup> </sup>(Sigma) to obtain a maximum of 285 histidine-positive clones<sup> </sup>for 10 million diploids screened. For all selected clones, lacZ<sup> </sup>activity was measured in a 96-well plate luminometric assay<sup> </sup>(Tropix). Inserts of all positive clones were amplified by PCR<sup> </sup>(7) and then sequenced on an ABI 3700 automatic sequencer (Applied<sup> </sup>Biosystems).<sup> </sup>
Bioinformatic analyses. Screening results from the Cys and Pro libraries were analyzed<sup> </sup>separately. Amino acid sequences of selected P-PV and P-Mok<sup> </sup>binding peptides were compared and aligned. The clustering of<sup> </sup>these sequences into subfamilies was calculated and displayed<sup> </sup>with neighbor-joining and unweighted pair group methods with<sup> </sup>arithmetic mean dendrograms by using the Clustalw and Jalview<sup> </sup>programs (http://www.compbio.dundee.ac.uk/).<sup> </sup>
Viral transcription-replication interference assay. To measure the effect of peptide coexpression on the formation<sup> </sup>of the functional rabies virus transcription-replication complex,<sup> </sup>we used the viral reverse genetic assay as described previously<sup> </sup>(12). T7-driven pDEST53-peptide constructs were cotransfected<sup> </sup>(1 ?g) with the viral components (N, P, and L genes and<sup> </sup>luciferase negative-strand minigenomic RNA). Each of the 29<sup> </sup>pDEST53-peptide constructs was separately tested in duplicate.<sup> </sup>Interference in the functionality of the viral complex was quantified<sup> </sup>by measuring the amount of luciferase activity which is related<sup> </sup>to the remaining transcriptional activity of the RNP. Luciferase<sup> </sup>expression was measured with a Berthold luminometer by injecting<sup> </sup>100 ?l of luciferase assay reagent (E1501; Promega) into<sup> </sup>10 ?l of each centrifuged cellular extract and counting<sup> </sup>for 10 s.<sup> </sup>
SELDI-TOF ProteinChip MS analysis. Anti-Flag M2 monoclonal antibody (1.5 ?g M2 antibody;<sup> </sup>Sigma) was covalently cross-linked to preactivated ProteinChip<sup> </sup>arrays (PS20; Ciphergen) by incubation in a humidity chamber<sup> </sup>at room temperature for 1 h. Non-cross-linked sites were inactivated<sup> </sup>twice with 4 ?l of 1 M ethanolamine-HCl (pH 8.0) for 15<sup> </sup>min. The PS20 chip array was then assembled with a loading device<sup> </sup>(Bioprocessor) to wash each spot twice for 5 min with 300 ?l<sup> </sup>of 0.5% Triton X-100 in phosphate-buffered saline (PBS) followed<sup> </sup>by two washes with PBS (300 ?l).<sup> </sup>
After clarification by centrifugation at 3,900 [FONT=arial,helvetica]x[/FONT] g rpm (3 min),<sup> </sup>200-?l aliquots of a 48-h posttransfection cellular lysate,<sup> </sup>derived from a classical viral transcription-replication interference<sup> </sup>assay where P was replaced by flagged P, were spotted on the<sup> </sup>M2 antibody modified chip array and incubated at room temperature<sup> </sup>with gentle agitation for 2 h. The whole ProteinChip array was<sup> </sup>washed with PBS-0.1% Triton X-100 (300 ?l) and air dried<sup> </sup>after a brief wash with 5 mM HEPES (pH 7.5) (300 ?l).<sup> </sup>Then, to facilitate the ionization process, two successive volumes<sup> </sup>of 0.5 ?l of a saturated solution of sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic<sup> </sup>acid; Fluka) in 50% acetonitrile-0.5% trifluoroacetic acid were<sup> </sup>spotted on the array and allowed to air dry.<sup> </sup>
Analysis of the ProteinChip array was carried out in a PBS II<sup> </sup>mass reader (Ciphergen Biosystems, Inc). The data of each spot<sup> </sup>were averaged from 240 UV laser shots (intensity of 250) and<sup> </sup>analyzed by an automated data collection in positive mode and<sup> </sup>with an external calibration by using Ciphergen's standards<sup> </sup>(14).<sup> </sup>
Determination of inhibitory effect of peptides on cell infection by rabies virus. BSR cells were cultured in Labtek chambers (15,000 cells per<sup> </sup>chamber) for 24 h in Dulbecco's modified Eagle's medium (DMEM)<sup> </sup>supplemented with 10% fetal bovine serum at 37?C. Cells<sup> </sup>were transfected with 2 ?g of peptide-encoding plasmid<sup> </sup>with FuGENE (Roche Diagnostics) according to the manufacturer's<sup> </sup>protocol. At 6 h posttransfection, cell monolayers were washed<sup> </sup>twice with DMEM and then infected with rabies virus diluted<sup> </sup>in DMEM (PV strain, 5 PFU/cell). After incubation for 1 h, the<sup> </sup>medium was discarded, and cells were washed with DMEM and then<sup> </sup>incubated at 37?C and 5% CO<sub>2</sub> for 24 h in DMEM supplemented<sup> </sup>with 5% fetal bovine serum.<sup> </sup>
Infected cells were fixed with PBS-4% paraformaldehyde and permeabilized<sup> </sup>at 0?C with 80% acetone for 15 min. Rabies virus RNP generated<sup> </sup>by the infection were then detected by incubation of fixed cells<sup> </sup>with rabbit anti-RNP serum (incubation for 1 h at 37?C)<sup> </sup>followed by incubation with Texas Red anti-rabbit conjugate<sup> </sup>under the same experimental conditions. The detection of infected<sup> </sup>and transfected cells with the control GFP fusion expression<sup> </sup>vector was determined by immunofluorescence analysis (LEICA<sup> </sup>DMRB microscope). Under these conditions, 75 to 80% of cells<sup> </sup>were found infected, whereas 30 to 50% of cells were GFP positive,<sup> </sup>depending on the plasmid used.<sup> </sup>
The inhibition percentage of transfected cells expressing the<sup> </sup>peptide-GFP fusion was calculated as follows: [1 ? (percentage<sup> </sup>of peptide-GFP rabies virus-infected cells/percentage of control-GFP<sup> </sup>rabies virus-infected cells)] [FONT=arial,helvetica]x[/FONT] 100. For each duplicate, 50<sup> </sup>GFP-positive cells were examined for the presence of rabies<sup> </sup>virus RNP.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
[/SIZE]</th></tr></tbody></table>
Design of coactamer libraries. Two libraries were constructed to direct the synthesis in yeast<sup> </sup>of various intrinsically constrained peptides fused to the Gal4p<sup> </sup>activation domain. The peptide-encoding libraries based on the<sup> </sup>mimicry of natural bioactive peptides share the presence of<sup> </sup>an invariable backbone of either cysteine or proline residues<sup> </sup>delimiting hypervariable peptide loops. In each of our libraries,<sup> </sup>20 amino acid residues are hypervariable within a peptide total<sup> </sup>length of either 26 or 29 amino acid residues for the cysteine<sup> </sup>and proline libraries, respectively. The cysteine coactamer<sup> </sup>library sequence was C-X<sub>2</sub>-C-X<sub>5</sub>-C-X<sub>6</sub>-C-X<sub>5</sub>-C-X<sub>2</sub>-C, and the proline<sup> </sup>coactamer library sequence was PP-X<sub>5</sub>-P-X<sub>5</sub>-PPP-X<sub>5</sub>-P-X<sub>5</sub>-PP. In<sup> </sup>both sequences, X denotes a randomized position where an NNK<sup> </sup>degenerate DNA codon encodes all 20 natural amino acids. Moreover,<sup> </sup>the cysteine-rich backbone was designed to fit to a typical<sup> </sup>Cys<sub>2</sub>/Cys<sub>2</sub> zinc finger motif which would favor organometallic<sup> </sup>complex formation and potentially increase the structural diversity<sup> </sup>of the cysteine coactamer library. The cysteine and proline<sup> </sup>libraries have an estimated diversity of 1 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup> and 3 [FONT=arial,helvetica]x[/FONT] 10<sup>7</sup><sup> </sup>individual random peptides. Sequencing of 20 randomly chosen<sup> </sup>clones in each library showed 100% insertion rates. Respectively,<sup> </sup>37 and 47% of the clones in the cysteine and proline libraries<sup> </sup>coded for full-length peptides. Other clones corresponded to<sup> </sup>shortened versions, resulting from the occurrence of frameshifts<sup> </sup>and termination codons. Yeast strain Y187 was transformed with<sup> </sup>each library, generating two yeast coactamer libraries with<sup> </sup>estimated individual complexities of 2.1 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (cysteine coactamers)<sup> </sup>and 3.5 [FONT=arial,helvetica]x[/FONT] 10<sup>6</sup> (proline coactamers).<sup> </sup>
Identification of P-binding peptides. We screened the two coactamer libraries with two highly divergent<sup> </sup>but functionally interchangeable P's (12) derived from two phylogenetically<sup> </sup>distant lyssaviruses (PV and Mok) (15). Thus, selectivity of<sup> </sup>the screening procedure could be reinforced by cross-selection<sup> </sup>for interactors common to both baits. The results of these screening<sup> </sup>assays are presented in Table 1. The saturation of the screens<sup> </sup>was confirmed by the redundancy in the peptide sequences (see<sup> </sup>peptide occurrence in Table 2). The number of positive clones<sup> </sup>per million interactions tested shows that the P-Mok bait has<sup> </sup>selected six times more prey than the P-PV bait with both libraries<sup> </sup>(Table 1). The screening of both libraries with a Trp+ empty<sup> </sup>vector (pFL 39) (8) allowed us to discard seven false-positive<sup> </sup>prey selected in the cysteine constraint library with P-PV and<sup> </sup>P-Mok (data not shown). No such overlap was observed for the<sup> </sup>proline coactamer library screening.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 1. Yeast two-hybrid screening results
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 2. Characteristics of selected peptides
</td></tr></tbody></table> </td></tr></tbody></table></center>
Bioinformatic selection of peptides. In silico analysis with multialignment programs (ClustalW with<sup> </sup>Jalview display) was used to compare the sequence data of interacting<sup> </sup>peptides selected by both P-PV and P-Mok baits from each coactamer<sup> </sup>library screen. A total of 755 selected clones were analyzed<sup> </sup>(Table 1). The preliminary output obtained by computer program<sup> </sup>analysis revealed subfamilies of peptides characterized by sequence<sup> </sup>similarity. Based on this multiple-sequence comparison, to maximize<sup> </sup>the sequence diversity of the peptides retained for further<sup> </sup>experiments, one member of each identified subfamily of similarity<sup> </sup>was selected. This selection also took into account the most<sup> </sup>frequently occurring peptides and thus the total representativity<sup> </sup>of each subfamily. Thus, 11 Cys and 17 Pro peptides were selected.<sup> </sup>In addition, one Cys peptide monospecific for P-PV was also<sup> </sup>chosen for further analysis.<sup> </sup> Functional test of viral transcription-replication complex formation interference assay. Each of the 29 selected peptides was subcloned in a T7 mammalian<sup> </sup>expression vector and then tested in a reverse genetic viral<sup> </sup>RNP reconstitution assay. This assay allows a quantitative analysis<sup> </sup>of the formation of a functional viral RNP by luciferase activity<sup> </sup>measurement (12). By coexpressing each individual peptide in<sup> </sup>this assay, we measured its capacity to interfere with the viral<sup> </sup>transcription-replication complex (Fig. 2). The 100% value corresponds<sup> </sup>to the control experiment realized with the peptide expression<sup> </sup>vector without the peptide-encoding sequence (empty vector),<sup> </sup>giving an average luciferase activity of about 10<sup>6</sup> arbitrary<sup> </sup>units. The background was below 100 arbitrary units.<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">

View larger version (13K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 2. Interference effects of selected peptides on the transcription-replication activity of rabies virus PV RNP complex (shown as means ? standard errors [error bars]). The luciferase activity was indicated as 100% in the control experiment with the empty peptide expression vector (y axis). One hundred percent corresponds to an average luciferase activity of 10<sup>6</sup> units. The experiment was performed in duplicate.
</td></tr></tbody></table> </td></tr></tbody></table></center>
In this assay, the majority of the selected peptides was fully<sup> </sup>active, except for P11, P19, and C26. The latter was chosen<sup> </sup>as an internal control because of its monospecificity and single<sup> </sup>occurrence. This underlines the utility of a screening strategy<sup> </sup>with two different baits in yeast two-hybrid analysis. This<sup> </sup>approach provided functional data that could be superposed on<sup> </sup>the initial selection procedure and allowed us to select the<sup> </sup>10 most active peptides plus a weak one as a control (C26).<sup> </sup>The selected peptides were submitted to a biophysical analysis<sup> </sup>of RNP complex destabilization.<sup> </sup> SELDI-TOF ProteinChip MS analysis. To evaluate whether functional inhibition of the RNP complex<sup> </sup>could be correlated with an alteration of the N-P interaction,<sup> </sup>we developed a method by using a Ciphergen Biosystems mass spectrometer<sup> </sup>which associates ProteinChip technology with SELDI-TOF (MS).<sup> </sup>Briefly, this assay consists of a classical coimmunoprecipitation<sup> </sup>experiment in which the anti-Flag M2 monoclonal antibody is<sup> </sup>covalently cross-linked with an epoxy preactivated ProteinChip<sup> </sup>array (PS20) instead of using protein A-Sepharose beads as the<sup> </sup>immunoabsorbant. Protein extracts are prepared from cells cotransfected<sup> </sup>with plasmids coding for N and L, the rabies virus minigenome,<sup> </sup>and a flagged P-PV, which works as a hook allowing RNP complex<sup> </sup>retention and subsequent analysis by classical SELDI-TOF (MS).<sup> </sup>Using this approach, alterations in the protein profiling of<sup> </sup>the rabies virus N-P complex in the presence of coexpressed<sup> </sup>peptide can then be measured. By comparison with a control experiment<sup> </sup>without peptide (B spectrum) (Fig. 3), the destabilization of<sup> </sup>the N-P interaction is correlated to an increase in the P/N<sup> </sup>peak intensity ratio (Table 3). Characteristic spectra observed<sup> </sup>with different peptides are shown in Fig. 3. The C2 and P16<sup> </sup>peptides clearly destabilize the N-P interaction, whereas the<sup> </sup>C9 or C26 peptide had little or no effect on the N-P complex.<sup> </sup>As the N-P interaction plays a crucial role in the functionality<sup> </sup>of the viral replication-transcription complex, N-P interaction<sup> </sup>destabilization was used as a criterion to select six interfering<sup> </sup>peptides characterized by their increasing effects, two other<sup> </sup>peptides were kept as negative controls (C26 and C27) (Table<sup> </sup>3). As peptides P15 and P16 displayed similar SELDI-TOF (MS)<sup> </sup>profiles, only P16 was kept. Quantification of P and peptide<sup> </sup>expression levels in the mammalian cells used in the interference<sup> </sup>assay or SELDI-TOF experiments show a peptide/P ratio of 1,<sup> </sup>with a 30 nM concentration of each in the various cell extracts<sup> </sup>(data not shown).<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">

View larger version (26K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 3. Representative protein profiling of rabies virus N/P complex by ProteinChip SELDI-TOF (MS) analysis. Panels A and B correspond to control (Ctl) experiments with untransfected and RNP-expressing cells, respectively, and panels C, D, E, and F show results from peptide experiments.
</td></tr></tbody></table> </td></tr></tbody></table></center>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 3. Evaluation of N-P interaction destabilization by ProteinChip SELDI-TOF(MS)
</td></tr></tbody></table> </td></tr></tbody></table></center>
Inhibition of viral replication assay. To evaluate the antiviral activity of the 8 last selected peptides,<sup> </sup>they were subcloned into a GFP fusion mammalian expression vector<sup> </sup>(enhanced GFP-C1; Clontech). The rabies virus inhibition of<sup> </sup>replication assay consists of the transfection of BSR cells<sup> </sup>with plasmids encoding the peptides followed by infection with<sup> </sup>rabies virus (Table 4). One peptide (P29) was discarded because<sup> </sup>of its cytotoxic activity. Four peptides (C2, C6, C8, and P16)<sup> </sup>demonstrated a strong antiviral activity. Peptide C10, although<sup> </sup>slightly less active (57% inhibition), strongly reduced the<sup> </sup>size and number of virus inclusion bodies. However, this modification<sup> </sup>of the appearance of infected cells was not taken into consideration<sup> </sup>for the evaluation of inhibition, resulting in a potential underestimation<sup> </sup>of total antiviral activity.<sup> </sup> <!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 4. Inhibition of rabies virus replication in PV rabies-infected BSR cells
</td></tr></tbody></table> </td></tr></tbody></table></center>
The inhibitory activity of two peptides (C2 and P16) is illustrated<sup> </sup>in Fig. 4. Whereas 75 to 80% of cells were infected under the<sup> </sup>infection conditions used (as measured by RNP production; data<sup> </sup>not shown), the majority of transfected cells expressing selected<sup> </sup>peptides (as indicated by GFP expression) were found to be negative<sup> </sup>for rabies virus RNP expression (Fig. 4A to F), indicating high<sup> </sup>levels of virus inhibitory activity. In contrast, cells transfected<sup> </sup>with the control plasmid expressing GFP (control experiment)<sup> </sup>displayed a normal expression level of rabies virus RNP (Fig.<sup> </sup>4G to I) and no inhibition.<sup> </sup> <!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">

View larger version (47K):
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> FIG. 4. Inhibitory effect of peptides on infection by rabies virus. BSR cells were transfected with C2 plasmid (A to C), P16 plasmid (D to F), or empty plasmid in a control experiment (G to I). (A, D, and G) GFP fluorescence (note granular inclusions of GFP fusion with peptide C2 or P16); (B, E, and H) rabies virus RNP immunostaining with characteristic perinuclear dots (white arrows indicate transfected cells); (C, F, and I) merged GFP and rabies virus RNP immunostaining with 4',6'-diamidino-2-phenylindole (DAPI) coloration of cell nuclei. The majority of transfected cells expressing selected peptides (indicated by GFP expression) were found to be negative for rabies virus RNP.
</td></tr></tbody></table> </td></tr></tbody></table></center>
In summary, our results clearly indicate that selected peptides<sup> </sup>destabilize both the interaction and functionality of the lyssavirus<sup> </sup>N-P complex, an interference which could be detected in a viral<sup> </sup>reverse genetic assay, a particle-complex physical analysis,<sup> </sup>and a cell infection test.<sup> </sup> <!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
[/SIZE]</th></tr></tbody></table>
The rabies virus P is a main component of the RNP, providing<sup> </sup>the link between the N-enwrapped genomic RNA and the viral polymerase<sup> </sup>(3, 4, 12) and playing a role in retrograde transport through<sup> </sup>its interaction with cytoplasmic dynein (11, 18). All of these<sup> </sup>data suggest that rabies virus P could be a prime antiviral<sup> </sup>target. Moreover, rabies virus P was successfully used as a<sup> </sup>bait in previous two-hybrid screens (11, 12, 18), indicating<sup> </sup>that the resulting GAL4 binding domain-P fusion folds correctly<sup> </sup>in yeast cells.<sup> </sup>
Many studies with peptide aptamers have demonstrated the interest<sup> </sup>of combinatorial approaches in the identification of short peptide<sup> </sup>sequences able to mimic the large array of structures that characterize<sup> </sup>cellular proteomes. To be biologically active, these peptide<sup> </sup>aptamers (peptamers) require conformational constraints that<sup> </sup>are induced by their carrier proteins. In contrast to such peptamers,<sup> </sup>the coactamer concept developed in this study uses intrinsically<sup> </sup>constrained peptides mimicking natural bioactive peptides. Our<sup> </sup>approach involves a sequence of selective steps of increasing<sup> </sup>stringency, going from identification of interactors to functional<sup> </sup>inhibitors. Of the 755 P-binding peptides first selected in<sup> </sup>an exhaustive two-hybrid screening, in silico analysis identified<sup> </sup>subfamilies from which the most representative peptides were<sup> </sup>chosen by using as selection requirements both their frequency<sup> </sup>and their ability to bind to two lyssavirus P's (PV and Mok).<sup> </sup>These two highly divergent P's were previously demonstrated<sup> </sup>to be functionally interchangeable in a reverse genetic assay<sup> </sup>(12) and thus were chosen to reinforce the stringency of the<sup> </sup>selection process. This assumes that the interacting peptides<sup> </sup>common to both baits were binders to conserved functional regions,<sup> </sup>given that the 47% identity between the two P's is restricted<sup> </sup>to functionally important domains (12). Thus, peptides binding<sup> </sup>to both proteins are likely to interfere more strongly with<sup> </sup>the viral infectious cycle. This double selection in the two-hybrid<sup> </sup>procedure was combined with a viral reverse genetic assay consisting<sup> </sup>of an ex vivo reconstitution of a functional transcription-replication<sup> </sup>complex. A rather high proportion of peptides selected in this<sup> </sup>study are biologically active. As previously demonstrated with<sup> </sup>single-stranded antibody selection, this is likely to be related<sup> </sup>to the use of an in vivo selection (here, the yeast two-hybrid<sup> </sup>and the viral reverse genetic assay), which should facilitate<sup> </sup>the identification of in vivo valuable peptides (20). Peptides<sup> </sup>emerging as both P-interactors and the strongest transcription-replication<sup> </sup>inhibitors were studied with ProteinChip MS analysis for their<sup> </sup>capacity to destabilize the N-P interaction. Only partial destabilization<sup> </sup>was achieved with inhibitory peptides, which is in good agreement<sup> </sup>with the peptide/target ratio close to 1 which was observed<sup> </sup>under our experimental conditions. For the peptides C9 and P23,<sup> </sup>which were inhibitory in the viral reverse genetic assay but<sup> </sup>displayed no measurable destabilization of the N-P interaction,<sup> </sup>it seems likely that they may interfere with interactions, such<sup> </sup>as that of P and L, that also play a pivotal role in rabies<sup> </sup>virus RNP complex function. Unfortunately, the size discrepancy<sup> </sup>between L (220 kDa) and P (35 kDa) invalidates further investigations<sup> </sup>with ProteinChip MS analysis. Considering the lack of mechanistic<sup> </sup>evidence for some peptides, we have favored for further analysis<sup> </sup>only six peptides essentially characterized by their different<sup> </sup>SELDI-TOF (MS) profiles with increasing effects on N-P destabilization.<sup> </sup>This highly stringent selection might possibly have resulted<sup> </sup>in missing some of the peptides that would also be effective<sup> </sup>in suppressing the viral replication. Alternatively, a more<sup> </sup>pragmatic approach could also be envisaged, consisting of the<sup> </sup>direct selection of peptides for their antiviral activities<sup> </sup>and then of the investigation of the suppressive mechanism,<sup> </sup>provided that a multiparallel inhibition of infection assay<sup> </sup>could be designed. In this work, as the ultimate validation<sup> </sup>of our overall strategy for the identification of antiviral<sup> </sup>peptides, we have performed an ex vivo inhibition of viral replication<sup> </sup>assay with rabies virus. This assay constituted the most stringent<sup> </sup>test and resulted in the identification of four strong rabies<sup> </sup>virus inhibitory peptides (C2, C6, C8, and P16) whose general<sup> </sup>features in comparison with control peptides are displayed in<sup> </sup>Table 5. The overall structural diversity of the four strongest<sup> </sup>bioactive peptides suggests that a mixture of them could potentiate<sup> </sup>their therapeutic effect by affecting different P functional<sup> </sup>domains. Furthermore, these four peptides demonstrated no inhibition<sup> </sup>of cellular infection with the unrelated human immunodeficiency<sup> </sup>virus (HIV) type 1, further underscoring the specificity of<sup> </sup>the selected peptides for the rabies virus targets (data not<sup> </sup>shown).<sup> </sup>
<!-- null -->
<center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2"> <tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]
</nobr> </td><td align="left" valign="top"> TABLE 5. General features of selected bioactive and control peptides
</td></tr></tbody></table> </td></tr></tbody></table></center>
Interestingly, despite a larger selection of prey in the proline<sup> </sup>library, cysteine coactamers seem to be more active, suggesting<sup> </sup>that the presence of cysteine favors constraints inducing greater<sup> </sup>stability and affinity of interacting peptides. Structure prediction<sup> </sup>with the PROF algorithm within the PredictProtein program indicated<sup> </sup>that three peptides (C6, C8, and P16) have an overall propensity<sup> </sup>to assume an alpha-helical conformation. In contrast, peptide<sup> </sup>C2, which is the most active, did not exhibit significant helical<sup> </sup>content, suggesting that maximizing the helical content of a<sup> </sup>short peptide could constrain it into a rigid helix with no<sup> </sup>significant increase in inhibitory potency and binding affinity.<sup> </sup> Finally, the peptides identified in this report may be considered<sup> </sup>molecular starting points that are likely to facilitate the<sup> </sup>design of nonpeptide mimics chemically engineered via scaffolding<sup> </sup>approaches. It should be noted that proline-rich peptides could<sup> </sup>facilitate the development of peptidomimetic approaches, which<sup> </sup>frequently use alpha-substituted proline analogues. Alternatively,<sup> </sup>these peptides, after a tailored mutagenesis to generate super<sup> </sup>binders and the addition of a protein transduction domain such<sup> </sup>as HIV TAT (19) or Antennapedia peptide, could be directly submitted<sup> </sup>to pharmacological tests. Indeed, the use of peptide-mediated<sup> </sup>transduction, through arginine-rich segments (9), is currently<sup> </sup>being investigated for therapeutic use in animals.<sup> </sup>
Interestingly, in preliminary experiments for establishing the<sup> </sup>cysteine-rich peptide library in yeast cells, we selected peptides<sup> </sup>able to bind DNA on the His<sub>3</sub> promoter region (data not shown).<sup> </sup>Thus, the cysteine coactamer library may also be useful for<sup> </sup>the identification of a specific DNA binding peptide which could<sup> </sup>be screened in yeast one-hybrid experiments. For DNA viruses,<sup> </sup>the identification of specific binders of viral regulatory regions<sup> </sup>represents an interesting potential antiviral strategy which<sup> </sup>could complement the targeting of viral proteins.<sup> </sup>
In summary, this work shows that coactamer libraries are powerful<sup> </sup>tools for target validation as exemplified here in anti-rabies<sup> </sup>virus drug discovery with the viral P as a target. The resulting<sup> </sup>libraries are also valuable sources of novel molecules with<sup> </sup>implications for the development of a new type of anti-rabies<sup> </sup>virus treatment. Moreover, this conceptual approach and its<sup> </sup>related tools are applicable to other infectious diseases and<sup> </sup>in any context of pathway-based drug discovery.<sup> </sup>
<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
We thank Dinh Tam Huynh, Val?rie Huteau, and Catherine<sup> </sup>Gouyette for the special care given to synthesizing the long<sup> </sup>random oligonucleotides and Charles Roth and Andrew Borman for<sup> </sup>helpful discussions. We are indebted to Luc Selig for his important<sup> </sup>contribution to this work, and we thank Stephane Emiliani from<sup> </sup>INSERM U567 (Institut Cochin) for performing HIV type 1 cellular<sup> </sup>infection tests.<sup> </sup>
E.R. was a recipient of an M.E.N.R.T. fellowship.<sup> </sup>
<!-- null -->
<table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%"> <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%">
<!-- null --> * Corresponding author. Mailing address: Pasteur Institute, Departement de Virologie, 28, rue du Dr Roux, Paris 75015, France. Phone: 33 1 45 68 87 53. Fax: 33 1 45 68 89 66. E-mail: yjacob@pasteur.fr<script type="text/javascript"><!-- var u = "yjacob", d = "pasteur.fr"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script>.